Best Life Insurance for Cancer Survivors

Research Snapshot

• Topic: Life insurance for cancer survivors (Health Conditions & High-Risk Life Insurance)
• Target buyer: A U.S. consumer who previously received cancer treatment and now wants life insurance, understanding that underwriting varies by cancer type, stage, grade, treatment, recurrence history, time since treatment ended, current follow-up, age, and overall health
• Platforms included (7): openai, anthropic, deepseek, grok, perplexity, kimi, google
• Research date: 2026-09-22 (authoritative run date)
• Unique entities named across platforms: 22
• Qualifying entities: 10
• Eligibility rule: Named by at least two platforms during ranking discovery
• Ranking basis: Platform mentions, then average listed rank, then best listed rank

One standardized prompt was sent once to each included platform. Platform-reported research dates differ from the authoritative run date for some platforms (deepseek reported 2026-05-07 for Mutual of Omaha, 2026-05-09 for Prudential, 2026-05-12 for Banner Life, 2026-01-15 for Lincoln Financial and Protective, and 2026-06-01 for Symetra, John Hancock, and Ethos). Those dates are provenance metadata and do not independently prove freshness.

The Consensus Ranking

Questions This Section Answers

• What are the best life insurance carriers for cancer survivors in 2026?
• Which life insurance company did all seven AI platforms name for cancer survivors?
• How many AI platforms named each carrier for life insurance after cancer treatment?

Platform mentions count only platforms that named the entity during ranking discovery. Several platforms later completed fit assessments for entities they did not name during discovery, so mention counts and fit-assessment counts differ.

Which Option Is Best for Which Version of the Buyer Need?

Questions This Section Answers

• Which life insurance carrier should a cancer survivor choose if they cannot qualify for traditional underwriting at all?
• Is a guaranteed-issue whole life policy or a medically underwritten term policy better for a cancer survivor who finished treatment years ago?
• Which carrier should a cancer survivor pick if they want to avoid a medical exam?

1. Mutual of Omaha

Questions This Section Answers

• Is Mutual of Omaha worth it for a cancer survivor who cannot qualify for traditional life insurance, and what are its main drawbacks?
• What death benefit does Mutual of Omaha's guaranteed whole life policy pay if the insured dies of cancer in the first two years?
• Which cancer survivors should skip Mutual of Omaha's guaranteed-issue product and apply for term coverage instead?

Mutual of Omaha is the only carrier named by all seven platforms, and the consensus reason is its guaranteed-issue whole life product, which is marketed with no medical exam and no health questions for applicants generally within issue ages 45–85 (50–75 in New York) ^[1]. That makes it the clearest fallback in this index when a cancer history blocks traditional underwriting. It is not, however, a low-cost or high-coverage solution, and platforms disagreed sharply on how to characterize its simplified-issue Living Promise line.

Why it ranked here. Mutual of Omaha received seven mentions but the widest spread of listed positions in the index (best rank 1, average 6.14), because platforms weighted it very differently: openai ranked it first, while anthropic and grok placed it eighth and ninth. The high mention count reflects that every platform treated guaranteed-issue coverage as a necessary part of the answer for cancer survivors.

Best suited for. Survivors who cannot qualify for traditional or simplified-issue coverage; applicants within the stated issue ages; buyers prioritizing guaranteed acceptance and fixed premiums over low cost or large coverage; small final-expense or debt-related needs ^[4].

Main strengths for this use case. Guaranteed acceptance regardless of cancer type, stage, or treatment status for the guaranteed whole life product ^[2]; premiums that the company states never increase ^[5]; permanent lifetime coverage; a 30-day free-look period ^[6]; and a company that publicly acknowledges cancer underwriting depends on treatment history, remission, and recurrence factors ^[7]. One platform also noted Mutual of Omaha as an exception that does not treat certain preventive medications such as Tamoxifen as active treatment for final-expense underwriting ^[8]. .

2. Prudential

Questions This Section Answers

• Is Prudential or Banner Life better for a cancer survivor who wants affordable term life insurance after remission?
• Does Prudential offer guaranteed-issue or simplified-issue coverage for cancer survivors, or only fully underwritten term?
• What should a cancer survivor verify about Prudential's accelerated underwriting before applying?

Prudential is the strongest medically underwritten term option in this index by average listed position (2.67) and was named by six platforms. The consensus case is that Prudential is unusually willing to underwrite certain cancer histories, particularly early-stage breast, prostate, and thyroid cancers, but that this reputation rests largely on independent broker commentary rather than a published Prudential underwriting table.

Why it ranked here. Six platforms named Prudential, and it received first-place votes from google and perplexity. Its average listed position of 2.67 is the second-best in the index. The gap between its strong average and its second-place finish reflects Mutual of Omaha's perfect mention count.

Best suited for. Survivors with completed treatment, stable follow-up, and a need for traditionally underwritten term coverage; applicants seeking 10-, 15-, 20-, or 30-year level-premium term; applicants willing to compare a fully underwritten offer against other carriers rather than relying on accelerated underwriting alone ^[9].

Main strengths for this use case. Multiple independent sources describe Prudential as consistently the most aggressive with cancer underwriting, often approving survivors earlier than competitors and offering better rate classifications ^[10]. Google reported a specialized "Rx for Success" clinical underwriting program targeting breast, prostate, bladder, cervical, thyroid, and testicular cancers, with prostate cancer survivors potentially qualifying for Preferred rates if diagnosed over age 60 with organ-confined disease and undetectable PSA ^[11]. Term Essential offers multiple level-premium durations and conversion to permanent coverage without new underwriting, subject to policy terms ^[13]. PruFast Track accelerated underwriting is available for eligible applicants ages 18–60 at face amounts up to $1 million, with some sources citing up to $3 million on certain products ^[15].

Main limitations. No reviewed Prudential source publishes a cancer-survivor underwriting table or guaranteed eligibility rule ^[9]. Prudential's whole life options are restricted to final expense coverage, so survivors seeking traditional whole life must look elsewhere ^[19].

3. Pacific Life

Questions This Section Answers

• Is Pacific Life's no-exam accelerated underwriting actually available to a cancer survivor, or does a cancer history force full underwriting?
• How much more does Pacific Life's no-exam pathway cost than its fully underwritten rates?
• Which cancer survivors should avoid Pacific Life because of its 12-month post-treatment decline rule?

Pacific Life is the index's clearest no-exam option, named by six platforms with an average listed position of 3.17. Its PAL+ program routes applications among accelerated, modified, and traditional underwriting, and the accelerated pathway can provide up to $3 million of PL Promise Term with no medical exam for ages 18–60 at Standard or better ^[20]. The critical caveat, reported by multiple platforms, is that a major cancer history generally disqualifies applicants from that accelerated pathway.

Why it ranked here. Six platforms named Pacific Life, and it received a first-place vote from deepseek. Its average listed position of 3.17 is third-best in the index. The no-exam coverage limit of $3 million is far above guaranteed-issue maximums, which is why platforms treated it as a distinct buyer need rather than a substitute for Mutual of Omaha.

Best suited for. Survivors whose treatment ended more than one year ago and whose records support standard or better underwriting consideration; applicants seeking term coverage who may qualify for PL Promise Term and want a no-exam or reduced-exam pathway; applicants comfortable using an independent agent or broker to compare Pacific Life's tentative offer with other carriers ^[22].

Main strengths for this use case. A defined accelerated-underwriting pathway that can reduce examination burden for eligible applicants ^[20]. Automatic movement from accelerated to modified and then traditional underwriting, which may avoid restarting the application with a different process ^[24]. PL Promise Term offers level-premium periods of 10, 15, 20, 25, or 30 years, a stated minimum death benefit of $50,000, and conversion to PL Promise Conversion UL without new underwriting, subject to product terms ^[25]. Multiple platforms cited a low NAIC complaint index of 0.05 against an industry benchmark of 1.0 ^[27]. .

4. Banner Life

Questions This Section Answers

• Is Banner Life or Prudential better for a cancer survivor who wants the lowest term life premium after remission?
• Does Banner Life's accelerated underwriting accept a cancer history, or does it require traditional underwriting?
• What table rating or flat extra should a cancer survivor expect from Banner Life?

Banner Life has the best average listed position in the entire index (2.20) despite being named by only five platforms, and it received a first-place vote from kimi. The consensus case is that Banner offers the cheapest term rates for qualifying cancer survivors, uses a Standard Plus base class for health impairments rather than the more expensive Standard class, and does not penalize applicants for a family history of cancer.

Why it ranked here. Five platforms named Banner Life, and its average listed position of 2.20 is the strongest in the index. It ranks fourth rather than first only because four other carriers were named by more platforms. Its best listed position was 1.

Best suited for. Survivors with completed treatment and favorable follow-up seeking affordable level-term coverage; applicants seeking 10- to 40-year terms and potential conversion to permanent coverage; applicants willing to use an independent broker to compare Banner with multiple carriers before submitting a formal application ^[29].

Main strengths for this use case. Broad term-duration range including terms up to 40 years ^[29]. Banner uses a Standard Plus rate class when pricing health impairments, while most companies use a more expensive Standard rate, and non-tobacco substandard premiums are based on Standard Plus rates increased by 25% per table rating, except for cancer cases requiring a flat extra without a table rating ^[31]. Banner is one of the few major insurers that does not penalize applicants for a family history of cancer ^[33]. Conversion to LifeStep UL is available without additional medical underwriting, subject to policy terms ^[35]. One platform reported that cancers with five-year survival rates above 85%, such as thyroid, melanoma, testicular, and Hodgkin's lymphoma, are most likely to qualify for standard or near-standard underwriting after a sufficient remission period ^[36].

Main limitations. No publicly verifiable cancer-specific underwriting chart or guaranteed eligibility rule exists ^[29].

5. Lincoln Financial

Questions This Section Answers

• Is Lincoln Financial worth it for a breast cancer survivor, and what are its main drawbacks?
• Why does Lincoln TermAccel decline cancer survivors, and what is the alternative product?
• What temporary flat extra should a cancer survivor expect from Lincoln Financial?

Lincoln Financial is the index's specialist for breast and prostate cancer histories, named by five platforms with an average listed position of 5.60. The consensus case is that Lincoln's traditionally underwritten LifeElements product offers favorable medical underwriting for certain localized cancers, while its fast-tracked TermAccel product strictly excludes any personal cancer history within the past 10 years.

Why it ranked here. Five platforms named Lincoln Financial, but its average listed position of 5.60 is weaker than Banner's or Pacific Life's, and it received no first-place votes. Its best listed position was 2, from google.

Best suited for. Survivors more than 10 years past treatment, subject to current underwriting and the specific cancer history; applicants with breast or prostate cancer histories who want an insurer that publicly describes specialized underwriting approaches for those conditions; applicants seeking term coverage with a conversion option to qualifying Lincoln permanent coverage; applicants needing at least $250,000 of traditional LifeElements Level Term coverage ^[38].

Main strengths for this use case. Lincoln publicly states that its underwriting guidelines include specialized approaches for prostate and breast cancer and reports that some applicants with those histories receive standard rates ^[39]. Google reported that on average 54% of Lincoln's life insurance applicants with a history of breast cancer receive standard or better rates, often within 3 to 5 years after successful treatment for early-stage cases ^[40]. Lincoln uses temporary flat extra fees rather than permanent ones for medical impairments, typically dropping off after 2 to 7 years ^[41]. A table reduction program can shave substandard table ratings from Table 3 to Standard for permanent products through age 70 for face amounts up to $10 million ^[43]. LifeElements offers 10-, 15-, 20-, or 30-year level-premium periods with conversion to qualifying permanent coverage without new underwriting before the earlier of the end of the level-premium period or attained age 70 ^[44]. .

6. Protective

Questions This Section Answers

• Is Protective worth it for a cancer survivor who wants medically underwritten term or universal life coverage?
• Does Protective's accelerated underwriting accept a cancer history, and what happens if it does not?
• What should a cancer survivor verify about Protective's family history rules before applying?

Protective is the index's high-risk underwriting generalist, named by four platforms with an average listed position of 4.25 and a best listed position of 3 from openai. The consensus case is that Protective is recognized as a leader in high-risk life insurance underwriting and offers competitive term and universal life pricing, but that cancer is explicitly listed as an adverse underwriting consideration requiring full medical review.

Why it ranked here. Four platforms named Protective, and its average listed position of 4.25 is the third-strongest among the four-mention carriers. It received no first-place votes.

Best suited for. Survivors sufficiently removed from treatment who are willing to complete medical underwriting; applicants seeking traditionally underwritten term coverage with possible accelerated or instant underwriting if they qualify; applicants needing permanent coverage and able to support higher, policy-specific universal-life costs ^[45].

Main strengths for this use case. Protective is described by independent sources as the leader in high-risk life insurance underwriting and explicitly addresses cancer survivors in its product messaging ^[46]. Google reported a dual-reinsurance underwriting approach using both Swiss Re and Hannover Re manuals and taking the best rating from each, which often yields a 2–3 table rating improvement for applicants with medical risks ^[48]. Protective maintains a dedicated Quick Quote desk for financial professionals, enabling a preliminary risk assessment within 24 hours without a formal application ^[48]. Family history criteria only factor in whether a parent or sibling died from cancer prior to age 60, rather than whether they merely had an incidence of cancer ^[49]. Protective includes an accelerated death benefit rider at no extra cost that activates for chronic, critical, or terminal illness diagnoses ^[50].

Main limitations. Protective underwriting guidelines explicitly list cancer as an adverse underwriting consideration requiring full medical underwriting and individual case review ^[51].

7. Symetra

Questions This Section Answers

• Is Symetra worth it for an early-stage cancer survivor, and what are its main drawbacks?
• Which cancer types qualify for Symetra's Preferred Cancer Program, and what rate classes are available?
• What are the eligibility limits on Symetra's Cancer Care Compass rider for a cancer survivor?

Symetra is the index's most contested carrier, named by only three platforms but rated "strong" by two of them and "mixed" by five. The consensus case is that Symetra has explicit underwriting guidelines favorable to early-stage cancer survivors across several cancer types and offers a unique cancer-focused rider, but that its public materials do not disclose the specific waiting periods or rating thresholds a survivor needs to evaluate fit.

Why it ranked here. Three platforms named Symetra, and its average listed position of 5.67 is the weakest among the top seven. Its best listed position was 2, from kimi. The wide fit-rating split reflects genuine disagreement about how much weight to give Symetra's documented cancer specialty versus its lack of published underwriting detail.

Best suited for. Survivors of early-stage breast, cervical, colon, prostate, skin, testicular, or thyroid cancer seeking competitive rates; applicants in remission for 2 or more years with clear follow-up results; buyers aged 20–80 seeking term coverage or ages 20–85 seeking indexed universal life with permanent coverage; survivors comfortable with higher minimum coverage amounts ^[54].

Main strengths for this use case. Symetra has explicit underwriting guidelines favorable to early-stage cancer survivors, with published emphasis on breast, cervical, colon, prostate, skin, testicular, and thyroid cancers ^[54]. Multiple independent reviews identify Symetra as "excellent" and "best overall" for cancer survivors ^[55]. Symetra Term is available ages 20–80 with coverage from $250,000, and SwiftTerm is available ages 20–60 covering $100,000–$5 million with accelerated underwriting and possible no-exam decisions ^[58]. The Cancer Care Compass rider package on select indexed universal life policies includes Galleri multi-cancer early detection test access, a cancer diagnosis cash benefit, and health advocacy services ^[60]. Symetra holds an A (Excellent) AM Best rating with a stable outlook affirmed May 2026 and a NAIC complaint index of 0.18, roughly 82% fewer complaints than average ^[62]. .

8. Transamerica

Questions This Section Answers

• Is Transamerica worth it for a cancer survivor who needs final expense coverage, and what are its main drawbacks?
• What cancer histories does Transamerica automatically decline for its final expense policies?
• How much does Transamerica's final expense coverage cost per month for a 60-year-old cancer survivor?

Transamerica is the index's final-expense specialist, named by three platforms with an average listed position of 8.00 and a best listed position of 5 from anthropic. The consensus case is that Transamerica's simplified-issue final expense portfolio offers fast decisions and no medical exam, but that it strictly declines recent, metastatic, recurrent, or multiple cancer histories on the initial screening questionnaire.

Why it ranked here. Three platforms named Transamerica, but its average listed position of 8.00 is the weakest in the index. It received no first-place votes. The low average reflects that platforms treated final expense as a fallback category rather than a primary recommendation for cancer survivors.

Best suited for. A cancer survivor seeking approximately $1,000–$50,000 of permanent final-expense coverage; applicants who prefer simplified underwriting and may qualify without an exam or laboratory testing; applicants who are older or have health history that makes traditional underwriting difficult, subject to Transamerica's actual eligibility rules ^[64].

Main strengths for this use case. Transamerica's Final Expense Solutions Portfolio consists of nonparticipating whole life products with simplified underwriting and potential same-day approval without exams or labs ^[64]. Google reported that applicants cancer-free and treatment-free for more than 2 years qualify for Standard rates on the Immediate Solution policy, and those past 3 years can qualify for Preferred rates ^[67]. One platform reported that Transamerica is more lenient on paired diagnoses such as diabetes with COPD or heart disease with stents, which may help survivors with additional conditions ^[68]. Coverage amounts range from $1,000 to $50,000 depending on product and age, with Immediate and 10-Pay maximums ranging from $50,000 at issue ages 0–55 to $25,000 at ages 76–85 ^[64]. The Everest Funeral Concierge Service is included at no additional cost ^[70].

Main limitations. Public materials do not disclose cancer-specific rules addressing cancer type, stage, grade, treatment completion, recurrence, follow-up, or time since treatment ^[64].

9. John Hancock

Questions This Section Answers

• Is John Hancock worth it for a cancer survivor who wants wellness-linked premium discounts, and what are its main drawbacks?
• Does John Hancock offer whole life insurance for cancer survivors, or only term and universal life?
• How much does the Vitality PLUS rider cost, and how much premium savings can a cancer survivor realistically earn?

John Hancock is the index's wellness-incentive option, named by only two platforms but with a strong average listed position of 4.50 and a best listed position of 2 from perplexity. The consensus case is that John Hancock is noted among carriers with competitive cancer underwriting and offers a unique Vitality program that can reduce premiums for health-engaged survivors, but that its cancer-specific underwriting benchmarks are not publicly disclosed.

Why it ranked here. Only two platforms named John Hancock during ranking discovery, which caps its rank at ninth despite a strong average listed position. Its best listed position of 2 reflects that perplexity ranked it highly.

Best suited for. Cancer survivors whose treatment is complete, follow-up is stable, and current health supports conventional underwriting; applicants seeking term coverage with possible conversion rights or permanent coverage with cash-value features; applicants who value wellness rewards and may qualify for Vitality premium savings ^[71].

Main strengths for this use case. John Hancock is listed among insurers known for competitive cancer underwriting and is described as having strong underwriting for survivors 5 or more years out ^[72]. Google reported that Preferred rating classes are potentially available for survivors of specific early-detected, successfully treated cancers: thyroid, uterine, and testicular cancers may qualify after 5 years, prostate cancer after 10 years, and general cancers without metastasis or recurrence after 20 years ^[74]. The Vitality program offers premium savings of up to 25% at sustained full engagement on the Vitality PLUS tier, and Vitality GO is bundled into every policy at no extra cost ^[75]. Eligible Vitality customers may access the Galleri multi-cancer early detection test, Prenuvo whole-body MRI access, and Function Health membership pricing ^[77]. Term policies are convertible to permanent coverage without additional medical underwriting, subject to policy terms ^[79].

10. Ethos

Questions This Section Answers

• Is Ethos worth it for a cancer survivor who wants a fast online term life application, and what are its main drawbacks?
• Does Ethos decline cancer survivors, and what happens if a term application is declined?
• How much more expensive is Ethos term life than the national average for a cancer survivor?

Ethos is the index's digital-first option, named by only two platforms with an average listed position of 4.50 and a best listed position of 4 from deepseek. The consensus case is that Ethos offers a convenient online application with automatic routing to other products if a term application is declined, but that cancer history commonly triggers declines or non-competitive pricing on its primary term product.

Why it ranked here. Only two platforms named Ethos during ranking discovery, which caps its rank at tenth despite a strong average listed position. Its best listed position of 4 reflects that deepseek ranked it highly.

Best suited for. Cancer survivors with completed treatment and stable follow-up who value a fast online application; applicants seeking ordinary term coverage and willing to accept medical-data review or possible escalation to full underwriting; applicants who want an initial quote without assuming that a no-exam pathway will be available ^[80].

Main strengths for this use case. Ethos uses an automatic laddering system that routes declined applicants through progressively more lenient products: Term Life Prime, Term Life Choice, Advantage Whole Life, and finally Guaranteed Acceptance Whole Life ^[82]. This avoids outright denials and ensures some coverage is available. No medical exam is required for simplified underwriting policies, only online health questions and verification through pharmacy records, electronic medical records, and motor vehicle reports ^[81]. Most simplified-issue applicants receive same-day approval, and when additional review is needed the process may take a few days, significantly faster than traditional carriers ^[87]. Ethos offers a 30-day money-back guarantee with no cancellation fees after the first 30 days ^[89]. Term lengths up to 40 years are available ^[91].

Main limitations. Cancer history commonly triggers declines or non-competitive pricing on term life, the primary use-case product ^[92].

What the Cross-Platform Study Reveals About This Market

Questions This Section Answers

• What does the cross-platform AI study reveal about how life insurers treat cancer survivors?
• Why do AI platforms recommend guaranteed-issue coverage so often for cancer survivors?

The single most consistent finding across all seven platforms is that the market for cancer survivors splits into two distinct product tiers, and that the right answer depends almost entirely on how far past treatment the applicant is. The first tier is guaranteed-issue or simplified-issue permanent coverage, generally capped at $25,000–$50,000, with a two-year graded benefit for natural death. The second tier is medically underwritten term or permanent coverage, which can provide $250,000 to $3 million or more but requires a remission period that platforms variously described as 2 years, 3–5 years, 5 years, 10 years, or 20 years depending on cancer type and stage.

A second finding is that no platform could produce a complete, current, cancer-type-by-cancer-type underwriting table from any carrier. Every carrier in this index either publishes general educational statements about cancer underwriting or publishes product-specific guides that cover only a subset of cancers.

Where the AI Platforms Agreed

Questions This Section Answers

• Which life insurance carriers do all AI platforms agree are worth considering for cancer survivors?
• What do AI platforms agree on about the limits of guaranteed-issue coverage for cancer survivors?

Platforms agreed on several points that buyers can treat as the most reliable findings in this index.

• Guaranteed-issue coverage is a necessary fallback. Every platform that named Mutual of Omaha described its guaranteed whole life product as relevant when a cancer history blocks traditional underwriting ^[94].
• Guaranteed-issue coverage is small and graded. Platforms consistently reported face amounts of roughly $2,000–$25,000 and a two-year graded benefit paying 110% of premiums for non-accidental death ^[101].
• A cancer history generally disqualifies applicants from accelerated no-exam underwriting. This was reported for Pacific Life, Banner Life, Protective, Symetra, and Ethos ^[104]. .

Where the AI Platforms Disagreed

Questions This Section Answers

• Why do AI platforms disagree about whether Prudential and Symetra are the best carriers for cancer survivors?
• Which carrier recommendations for cancer survivors are most contested across AI platforms?

The most consequential disagreements in this index are about how much weight to give independent broker reputation versus published carrier documentation.

• Prudential's cancer underwriting reputation. Anthropic and kimi rated Prudential "strong" based on independent broker consensus that it is the most cancer-friendly major carrier ^[109][e2:kimi:lifeinsureguide.com-1]. Openai and deepseek rated it "mixed" because no Prudential source publishes cancer-specific underwriting rules ^[110].
• Symetra's cancer specialty. Anthropic and grok rated Symetra "strong" based on its Preferred Cancer Program and independent reviews ^[112]. Five other platforms rated it "mixed" because no public Symetra source publishes cancer-type-specific underwriting rules ^[114].
• Pacific Life's no-exam pathway. Anthropic and kimi described PAL+ as explicitly accommodating in-remission survivors ^[117]. Openai and google emphasized that a major cancer history is a hard barrier to the accelerated pathway ^[119]. .

How Buyers Should Choose

Questions This Section Answers

• What should a cancer survivor check before choosing a life insurance carrier?
• How should a cancer survivor decide between guaranteed-issue coverage and medically underwritten term coverage?

The decision sequence that emerges from this index is straightforward, and it depends on facts only the buyer has.

Step 1: Establish the cancer facts. Write down the cancer type, stage, grade, treatment modalities, treatment completion date, recurrence history, current surveillance schedule, and current medications. Every carrier in this index evaluates these factors, and no platform could predict an individual outcome without them ^[121].

Step 2: Determine whether traditional underwriting is realistic. If treatment ended more than 1 year ago and follow-up is stable, medically underwritten term coverage from Prudential, Banner Life, Pacific Life, Lincoln Financial, Protective, or Symetra may be available and will generally provide far more coverage per premium dollar than guaranteed-issue coverage ^[124]. .

Methodology

This index was produced from a single standardized prompt sent once to each of seven AI platforms on 2026-09-22: openai, anthropic, deepseek, grok, perplexity, kimi, and google. The prompt asked which life insurance carriers are generally worth considering for cancer survivors and why, with the buyer described as a consumer who previously received cancer treatment and understands that underwriting may vary substantially based on cancer type, stage, grade, treatment, recurrence history, time since treatment ended, current follow-up, age, and overall health.

Entities were extracted from platform responses and normalized to company-level identity. An entity qualified for the final ranking if it was named by at least two of the seven platforms during ranking discovery. Ten entities qualified out of 22 unique entities named.

The final ranking order is determined by platform mentions, then average listed position, then best listed position. The ranking table is the sole authority for rank, platform mentions, platform share, average rank, and best rank. Platform mentions count only ranking-discovery mentions and do not include platforms that later completed a fit assessment without naming the entity during discovery. .

Methodology Limitations

Several limitations apply to every finding in this index.

• One prompt, one run. The study used one standardized prompt sent once to each included platform. AI answers can vary by date, wording, location, account state, model, interface, browsing configuration, and the sources retrieved. A repeat run could produce different results.
• Platform-reported evidence is not independently verified. Citations are platform-reported evidence, not independently verified facts. No-search model claims require explicit verification before being described as current facts.
• Platform-reported research dates differ from the authoritative run date. Deepseek reported 2026-05-07 for Mutual of Omaha, 2026-05-09 for Prudential, 2026-05-12 for Banner Life, 2026-01-15 for Lincoln Financial and Protective, and 2026-06-01 for Symetra, John Hancock, and Ethos. These dates are provenance metadata and do not independently prove freshness.
• Some platforms did not complete a fit assessment for every entity they named. Pacific Life and Transamerica each had 6 of 7 platforms return a usable fit assessment. Ethos had 6 of 7. Fit findings for those entities should not be described as unanimous.
• Company-owned citations materially outnumber independent citations for some entities. This applies to Pacific Life, Banner Life, and Protective. Company claims should not be described as independently verified. .

Final Verdict

Mutual of Omaha is the consensus leader for life insurance for cancer survivors in this 7-platform study, named by all seven platforms, because its guaranteed-issue whole life product provides a coverage path when a cancer history blocks traditional underwriting. It is not the best option for every survivor: its coverage is small, its early natural-death benefit is graded, and its pricing is generally higher per dollar of protection than medically underwritten alternatives.

For survivors with a favorable remission history, the strongest alternatives are Prudential and Banner Life for medically underwritten term coverage, Pacific Life for a no-exam accelerated pathway up to $3 million, and Lincoln Financial for breast or prostate cancer histories more than 10 years past treatment. Protective and Symetra round out the medically underwritten tier with different underwriting philosophies. Transamerica is the strongest final-expense option for survivors who need modest permanent coverage and can pass simplified-issue screening. John Hancock and Ethos serve narrower needs: wellness-linked premium discounts and fast digital applications, respectively.

The decisive variable is not the carrier ranking. It is the buyer's cancer history, and no platform in this study could predict an individual underwriting outcome from public information.